Research programme: cancer therapeutics - Ability Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Ability Pharmaceuticals

Alternative Names: ABTL 0814; ABTL 0815; ABTL 1014; ABTL 1216; LP20104

Latest Information Update: 05 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals
  • Class
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies

Most Recent Events

  • 05 Jan 2017 Preclinical development is ongoing for haematological malignancies and cancer in Spain (Ability Pharmaceuticals pipeline, January 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Spain (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top